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INTRODUCTION
Tardive dyskinesia (TD) is one of the most serious adverse 
effects of antipsychotic medication. The typical symptoms of 
TD are involuntary movements of the orofacial musculature. 
However, the trunk and extremities may also be affected. TD 
is known to appear in 20-30% of schizophrenic patients treat-
ed with typical neuroleptics.
1,2 Although the risk of TD is repor-
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tedly lower for newer atypical antipsychotics than for typical 
antipsychotics, it has not been ascertained whether there has 
been an associated decrease in the prevalence of TD.
3
Only a certain portion of patients exposed to long-term tr-
eatment with antipsychotic drugs develop TD, which suggests 
that individual susceptibility, such as genetic factors, is impor-
tant. Genetic vulnerability to the development of TD has been 
suggested based on the results of studies in animals
4 and hu-
mans (i.e., families).
5 Several biological mechanisms underly-
ing TD have been hypothesized, including dopamine receptor 
supersensitivity,
6 the dysfunction of the serotonergic system,
7 
gamma-aminobutyric acid insufficiency,
8 and disturbances in 
antioxidative protection.
9 However, the pathophysiology of 
TD is not well understood.
Dopamine receptor hypersensitivity hypothesis is based on 
several observations.
10 Neuroleptic-induced dyskinesia in a non-
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DRD2 Variants and Tardive Dyskinesia 
human primate showed significantly decreased dopamine turn-
over in the caudate and substantia nigra.
11 The dopamine D2 
recepto (DRD2) density in the basal ganglia after continuous 
antipsychotic treatment of rats also increased.
12-14 In addition, 
Acute behavioral responses to the administration of dopamine-
agonist following the withdrawal of antipsychotics have been 
reported in rat models.
15-17 Many studies have revealed that ty-
pical antipsychotics that generally have higher affinities for 
DRD2 is more likely to develop TD compared to atypical anto-
psychotics which have relatively lower affinities for it.
18-20 Thus, 
variation in DRD2 function and expression may contribute to 
the risk of antipsychotic-induced TD. 
Some previous studies reported the relationship between 
DRD2 variants and TD. Chen et al.
21 reported that the freq-
uency of the TaqI A2/A2 genotype of the DRD2 was higher in 
Taiwanese female schizophrenic patients with TD than those wi-
thout TD. Recently, there was the report that allelic and hap-
lotypic association between the DRD2 TaqIA/TaqIB variants 
and TD in a Chinese population.
22 Zai et al.
23 analyzed twelve 
DRD2 polymorphisms in TD and found that haplotypes con-
taining rs6275 (NcoI) and rs6277 were associated with TD. 
However, the association between DRD2 and TD was not con-
firmed by other studies.
24-29 Recently a meta-analysis reported 
the positive association between DRD2 TaqIA and TD.
30 How-
ever, the odds ratios (ORs) were only ranged from 1.1 to 1.5. 
These inconsistent findings suggest that the relationship re-
mains controversial.
These contradictory results prompted us to investigate whe-
ther the DRD2 gene plays a role in the susceptibility to TD in Kor-
ean schizophrenic patients. In the present study, we investigat-
ed the possible association between 5 polymorphisms of the 
DRD2 gene and TD.
METHODS
Subject and assessment
Two hundred and sixty three unrelated Korean schizoph-
renic patients participated in this study (100 TD and 163 non-
TD patients), all of whom were inpatients enrolled from the 
three collaborating hospitals of Korea University Hospital. 
This study was approved by the Ethics Committee of the Ko-
rea University Hospital, and written informed consents were 
obtained from all the participants. All patients met the criteria 
for a diagnosis of schizophrenia as determined by board-cer-
tified psychiatrists using the Korean version of the Structured 
Clinical Interview for the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders.
31 Subjects with signifi-
cant comorbid neurological illness, mental retardation, sub-
stance abuse, and other major psychiatric comorbidities were 
excluded. 
The participants consisted of schizophrenic patients with 
(n=100) and without (n=163) TD who were matched for anti-
psychotic drug exposure and other relevant variables. All of 
the non-TD had been treated with typical antipsychotics for 
at least 10 years. However, our sample included TD patients 
who had taken atypical antipsychotics (n=23) and who had 
been treated for less than 10 years (n=18). We applied these dif-
ferent inclusion criteria since the occurrence of TD in patients 
treated for less than 10 years is indicative of a higher genetic 
susceptibility. 
All of the subjects had taken the stable dosage of antipsy-
chotics for at least 3 months before TD was assessed. TD was 
diagnosed based on the Abnormal Involuntary Movement Sc-
ale (AIMS),
32,33 which measures the severity of involuntary mo-
vements in seven domains on a scale from 0 to 4. Subjects were 
considered to have TD when they had two or more 2-point rat-
ings, or one or more 3-point ratings in the first seven items of 
the AIMS. Psychopathology was measured using the Positive 
and Negative Syndrome Scale.
34 Other findings from these 
subjects have been reported previously.
35-40
Genotyping
We chose 5 single nucleotide polymorphisms (SNPs) [-141 
Cins>del (rs1799732), TaqIA(rs1800497), TaqID(rs1800498), 
Ser311Cys (rs1801028), NcoI (rs6275)] from DRD2 (Figure 
1), which spans about 270 kb where -141Cins>del is in the 
promoter region, TaqID is intron 2, rs6275 is in exon 7. TaqIA 
is in the 3’-untranslated region, which is in fact located in a 
novel gene, untitled X-kinase gene.
41 The SNP selection was 
based on the previous studies and minor allele frequency in 
Asian population. Blood samples (5-10 mL) were collected 
into EDTA tube, and genomic deoxyribonucleic acid (DNA) 
was isolated using NucleoSpin Genomic DNA Extraction Kit 
(Macherey-Nagel, Germany) according to standard proce-
Figure 1. Loci of the DRD2 polymorph-
isms we studied. DRD2: dopamine D2 
receptor gene, ANNK1: Ankirin kinase 1 
gene.
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dures. Genotyping of TaqIA and TaqID was modified on the 
basis of Kaiser et al.,
42 while analysis of -141Cins>del was 
modified according to Jönsson et al.
43 The Ser311Cys polymor-
phism was typed as previously described.
44 NcoI polymor-
phism (rs6275) was genotype as described by Sarkar et al.
45 
Statistical analysis
The presence of Hardy-Weinberg equilibrium was tested 
with the χ2 test for goodness of fit. Categorical data were also 
analyzed by using the χ2-test and differences for continuous 
variables were evaluated by using the Student’s t-test or analy-
sis of covariance. The cutoff p value was set at 0.05. We per-
formed haplotype-based case-control analysis of the 5 SNPs. 
Haplotype and linkage disequilibrium (LD) analyses were per-
formed using the software SNPAlyze version 7 (DYNACOM 
Co., Ltd. Yokohama, Japan). Overall distribution of haploty-
pes was analyzed using 2 X m contingency tables, with a p val-
ue of <0.05 considered to indicate statistical significance. The 
p value of each haplotype was determined using chi-square an-
alysis, the permutation method, and SNPAlyze version 7. Pair-
wise LD patterns were evaluated using D’. The power analysis 
was performed with using of G*Power 3.1.2 software.
46
RESULTS
The genotypic frequencies of the five DRD2 polymorphisms 
were within the Hardy-Weinberg equilibrium. Table 1 shows 
the demographic characteristics (age and sex) as well as total 
AIMS scores and TD diagnoses with genotypes and allele fre-
quencies of the 5 SNPs in DRD2. This study had a power of 
approximately 0.70 to detect a small effect size of 0.20 and 0.98 
to detect a medium effect size of 0.30 in the genotype frequ-
encies (n=263 for total sample). There was no significant dif-
ference in age, gender, and total AIMS score among the geno-
type groups. There was also no significant difference in the dis-
tribution of genotypic frequencies among patients with TD and 
without TD (TaqIA: chi-square=0.91, df=2, p=0.634; TaqID: 
chi-square=2.56, df=2, p=0.279; NcoI: chi-square=0.23, df=2, 
p=0.892; Ser311Cys: Fisher’s exact test, two tailed, p=0.326; 
-141Cins>del: chi-square=0.78, df=2, p=0.677) (Table 1). In ad-
dition, there is no significant difference in the distribution of al-
lele frequencies between patients with TD and without TD (Ta-
qIA: Fisher’s exact test, two tailed, p=0.588; TaqI B: Fisher’s exact 
test, two tailed, p=0.121; NcoI: Fisher’s exact test, two tailed, p= 
0.857; Ser311Cys: Fisher’s exact test, two tailed, p=0.352; -141 
Cins>del: Fisher’s exact test, two tailed, p=0.892) (Table 1). 
Table 1. Statistical analyses on demographics as well as total AIMS scores and TD diagnoses with genotypes and allele frequencies of the 
5 SNPs in DRD2 
DRD2 markers Genotype Allele frequencies Gender (M/F) Age (years) AIMS score (total) TD (yes/no)*
TaqIA (rs1800497) A1/A1 A1  0.57/0.54 46/39 42.02±8.65 2.89±3.49 29/56
A1/A2 A2  0.43/0.46 60/63 45.16±9.45 3.57±4.44 50/73
A2/A2 34/21 45.44±9.39 2.93±3.66 21/34
p p=0.588 p=0.268 p=0.30 p=0.414 p=0.634
TaqID (rs1800498) D1/D1 B1  0.93/0.965 127/110 44.00±9.05 3.35±3.96 93/144
D1/D2 B2  0.07/0.035 12/11 045.87±11.05 2.18±4.41 7/16
D2/D2 1/2 047.67±14.84 0.00±0.00 0/3
p p=0.121 p=0.779 p=0.531 p=0.158 p=0.279
NcoI (rs6275) C/C C   0.52/0.465 33/26 44.61±9.23 2.29±3.04 21/38
C/T T   0.48/0.535 67/63 45.06±9.62 3.60±4.46 51/79
T/T p=0.857 40/34 42.38±8.54 3.26±3.70 28/46
p p=0.843 p=0.129 p=0.116 p=0.892
Ser311Cys (rs1801028) Ser/Ser Ser  0.90/0.925  110/105 44.00±9.32 3.30±4.12 85/130
Ser/Cys Cys  0.10/0.075 30/18 45.10±9.12 2.83±3.41 15/33
Cys/Cys 0/0 0/0
p p=0.352 p=0.200 p=0.459 p=0.465 p=0.326
-141Cins>del (rs1799732) Ins/Ins Ins  0.87/0.88 109/95 43.77±8.62 3.22±3.88 79/125
Ins/Del Del  0.13/0.12 28/25 045.21±11.49 2.94±4.35 18/35
Del/Del 3/3 50.00±7.80 5.33±4.68 3/3
p p=0.892 p=0.984 p=0.183 p=0.382 p=0.677
*5 SNPs were not associated with TD. AIMS: Abnormal Involuntary Movement Scale, TD: tardive dyskinesia, SNPs: single nucleotide polymor-
phisms, DRD2: dopamine D2 receptors 52  Psychiatry Investig 2011;8:49-54
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Haplotype analysis
Seventeen haplotypes were found in the present study (data 
not shown), 9 of which had a frequency of more than 1% (Ta-
ble 2). The most frequent two haplotypes were I-D1-T-C-A1 
and I-D1-C-C-A2 (36.7% and 35.5%, respectively). Overall 
haplotype (-141Cins>del/TaqID/NcoI/Ser311Cys/TaqIA) 
frequency was also not significantly different between TD and 
non-TD groups, although one rare haplotype (I-D1-T-G-A1) 
showed significantly different frequency between TD and non-
TD groups (2.7% vs. 8.5%, respectively, p=0.031).
DISCUSSION
Previous studies showed inconsistent results in the associa-
tion between DRD2 polymorphisms and TD. Zai et al.
23 expl-
ained these reasons as different polymorphisms used in many 
of the studies, few haplotype analyses, different ethnic back-
grounds, small sample size, and the use of dichotomous TD 
occurrence for the analyses. Thus, in our study, haplotype an-
alyses as well as SNP analyses were used, and only Korean sub-
jects participated in our study. In addition, most analyzed DRD2 
polymorphisms except NcoI were used. As a result, none of 5 
polymorphisms were found to be significantly associated with 
TD and with TD severity as measured by AIMS. Haplotype 
distributions were also found to be not significantly different 
between TD and non-TD groups. 
On the contrary, it was reported that A2/A2 genotype and 
A2 alleles of TaqIA were significantily associated with TD in 
Taiwanese females.
21 Furthermore, the results from the meta-
analysis suggest that TaqIA is associated with TD. However, the 
relatively low OR suggested that it is consistent with the idea of 
contributions of multiple genetic variants in complex pheno-
types.
30 Additionally, TaqIA association with TD could not be 
replicated in several study,
23,29 in which the authors suggested 
that the previous positive finding with TaqIA could be due to 
higher LD in the 3’ portion of DRD2. They also assumed this 
polymorphism is located 10 kb upstream of the 3’ non-coding 
region of the gene. Other results except NcoI from our study 
are consistent with most previous studies in that TaqID, Ser-
311Cys, -141Cins>del polymorphisms were found to be not 
significantly associated with TD.
23,26-28,30,47,48 Especially, the re-
sults from the meta-analysis showed that the -141Cins>del al-
leles and genotypes were not associated with TD although the 
sample size was so small.
30 
There are several limitations to generalization of the results 
of this study. First, although anticholinergics and benzodiaz-
epines have been reported to be beneficial in some cases of TD, 
in this study, we could not control those drugs. Secondly, we 
cannot exclude presence of population stratification bias. How-
ever, we do not think that stratification bias should be consider-
ed seriously in our sample because the Korean population is 
characterized by a genetic homogeneity.
49 Third, the relatively 
small sample size limits the generalizationabilty of our findings. 
Because our sample size is relatively small, our data cannot ex-
clude the possibility that DRD2 polymorphism has an influ-
ence on susceptibility to TD. Taking these limitations into ac-
count, further investigations involving additional genes and 
markers and larger samples are warranted to fully understand 
the genetic pathophysiology of TD.
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